Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.60 |
| ▸ | GSK3A | P49840 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.39 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392816 | 0.88 | GSK3B (0.61) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL2332408 | 0.86 | GSK3B (0.60) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL1461697 | 0.86 | GSK3B (0.82) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL2333341 | 0.84 | GSK3B (0.53) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL1377235 | 0.83 | GSK3B (0.52) | GSK3BCDK2CDK1GSK3A | |
| SCHEMBL2334015 | 0.81 | GSK3B (0.50) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL2338792 | 0.80 | GSK3B (0.49) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL2331113 | 0.79 | GSK3B (0.73) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL2339971 | 0.77 | GSK3B (0.70) | GSK3BCDK2CDK1MAPK1 | |
| SCHEMBL2337608 | 0.76 | GSK3B (0.49) | GSK3BCDK2CDK1GSK3ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| US-7407981-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-07-05 | — | — | US | disclosed |
| US-7196109-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | disclosed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | OXSR1, CBR1, OXER1 | GSK3B 159/4885CDK2 549/4885CDK1 63/4885 |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | SIGMAR1, CYP2C8, CNR1 | GSK3B 3595/4885CDK2 2237/4885CDK1 2123/4885 |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK2 1855/4885CDK1 1006/4885 |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK2 1855/4885CDK1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.